SEGMENT DISCLOSURES (Tables)

6 Months Ended

Apr. 30, 2026

	Three months ended April 30,											Six months ended April 30,
	2026					2025						2026					2025
REVENUES:
Puerto Rico consulting	$	1,450,970				$	1,170,245					$	2,615,153				$	2,273,514
United States consulting		619,780					714,104						1,166,668					1,360,237
Europe consulting		625,633					532,695						1,209,528					1,253,953
Other		6,560					-						6,560					673
Total consolidated revenue	$	2,702,943				$	2,417,044					$	4,997,909				$	4,888,377

GROSS PROFIT¹:
Puerto Rico consulting	$	439,604		30.3	%	$	347,521			29.7	%	$	690,475		26.4	%	$	545,075		24.0	%
United States consulting		153,801		24.8	%		216,375			30.3	%		359,464		30.8	%		438,700		32.3	%
Europe consulting		308,555		49.3	%		254,830			47.8	%		574,395		47.5	%		602,387		48.0	%
Other		81		1.2	%		-		-		%		81		1.2	%		673		100.0	%
Total consolidated gross profit	$	902,041		33.4	%	$	818,726			33.9	%	$	1,624,415		32.5	%	$	1,586,835		32.5	%

INCOME (LOSS) FROM OPERATIONS²:
Puerto Rico consulting	$	160,524				$	43,937					$	137,395				$	(832	)
United States consulting		(51,840	)				(128,028	)					(111,708	)				(228,090	)
Europe consulting		69,752					10,837						80,633					77,218
Other		(33,760	)				(25,068	)					(56,179	)				(38,809	)
Total consolidated income (loss) from operations		144,676					(98,322	)					50,141					(190,513	)
OTHER INCOME, NET		94,677					199,186						225,702					301,028
Total consolidated income before income tax	$	239,353				$	100,864					$	275,843				$	110,515

Pharma-Bio Serv, Inc. 10-Q